Skip to main content

Table 3 Estimation of malaria attack ( Pv , Pf , all species) during the prophylactic phase (6 month) of Study 033

From: A retrospective analysis of the protective efficacy of tafenoquine and mefloquine as prophylactic anti-malarials in non-immune individuals during deployment to a malaria-endemic area

Data* Value** Source
Post deployment P. vivax relapse rate (%) amongst Study 033 subjects 1.23 Pv relapses (8/651) from CMR not original Study 033 FCSR (Equation 1)
Anti-relapse effectiveness (%) of primaquine 69.5 Estimated from John et al. 2012
Anti-relapse efficacy (%) of tafenoquine 86.3 Estimated from Walsh et al. 2004b
Anti-relapse efficacy of combined Study 033 post-exposure prophylaxis regimens 82.1 Estimated (Equation 5)
Pv attack rate (%) during prophylactic phase of Study 033 6.88 Estimated (Equation 7)
Ratio of Pf cases to Pv cases in 1999/2000 ADF deployment (InterFET) 0.146 Observed from 1999/2000 ADF deployment (Equation 4)
Pf attack rate (%) during prophylactic phase of Study 033 1.00 Estimated (Equation 8)
All malaria attack rate (%) during prophylactic phase of Study 033 7.88 Estimated (Equation 6)
  1. *Observed in Study 033, ADF deployment, assumed from literature or derived. **Rounded after calculation.